Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Biomarkers in inflammatory bowel diseases].

Roblin X, Cavaille A, Clavel L, Paul S.

Presse Med. 2014 Jan;43(1):66-73. doi: 10.1016/j.lpm.2013.11.004. Epub 2013 Dec 27. Review. French.

PMID:
24373717
2.

Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.

Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A.

Dig Liver Dis. 2014 Nov;46(11):974-9. doi: 10.1016/j.dld.2014.07.013. Epub 2014 Aug 2.

PMID:
25096964
3.

[Role of biological markers in inflammatory bowel disease].

Gisbert JP, González-Lama Y, Maté J.

Gastroenterol Hepatol. 2007 Mar;30(3):117-29. Review. Spanish.

PMID:
17374324
4.

Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives.

Chaabouni T, Manceau H, Peoc'h K.

Ann Biol Clin (Paris). 2016 Aug 1;74(4):385-94. doi: 10.1684/abc.2016.1172. Review.

PMID:
27492691
5.

Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.

Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.

J Crohns Colitis. 2015 Jan;9(1):50-5. doi: 10.1093/ecco-jcc/jju003. Epub 2014 Nov 26.

PMID:
25518048
6.

Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.

Voiosu T, Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B.

J Gastrointestin Liver Dis. 2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv.

7.

Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T.

J Crohns Colitis. 2015 Jan;9(1):33-40. doi: 10.1016/j.crohns.2014.06.012.

PMID:
25052347
8.

Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.

Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.

J Crohns Colitis. 2013 Oct;7(9):730-5. doi: 10.1016/j.crohns.2012.10.018. Epub 2012 Nov 21.

PMID:
23182163
9.

Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.

Ashorn S, Honkanen T, Kolho KL, Ashorn M, Välineva T, Wei B, Braun J, Rantala I, Luukkaala T, Iltanen S.

Inflamm Bowel Dis. 2009 Feb;15(2):199-205. doi: 10.1002/ibd.20535.

10.

Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.

Langhorst J, Boone J.

Drugs Today (Barc). 2012 Feb;48(2):149-61. doi: 10.1358/dot.2012.48.2.1732555. Review.

PMID:
22384454
11.

A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Menees SB, Powell C, Kurlander J, Goel A, Chey WD.

Am J Gastroenterol. 2015 Mar;110(3):444-54. doi: 10.1038/ajg.2015.6. Epub 2015 Mar 3. Review.

PMID:
25732419
12.

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.

Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T.

World J Gastroenterol. 2014 May 7;20(17):5031-5. doi: 10.3748/wjg.v20.i17.5031.

13.

The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.

Kolho KL, Sipponen T.

Scand J Gastroenterol. 2014 Apr;49(4):434-41. doi: 10.3109/00365521.2014.886719. Epub 2014 Mar 6.

PMID:
24597837
14.

Biological markers in inflammatory bowel disease: practical consideration for clinicians.

Mendoza JL, Abreu MT.

Gastroenterol Clin Biol. 2009 Jun;33 Suppl 3:S158-73. doi: 10.1016/S0399-8320(09)73151-3.

15.

[Indicators of inflammatory process in stool in diagnostics and monitoring of inflammatory bowel diseases].

Iwańczak B, Iwańczak F.

Pol Merkur Lekarski. 2015 Dec;39(234):389-92. Review. Polish.

PMID:
26802694
16.

Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.

Gisbert JP, Marín AC, Chaparro M.

Aliment Pharmacol Ther. 2015 Aug;42(4):391-405. doi: 10.1111/apt.13276. Epub 2015 Jun 15. Review.

17.

The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.

Henderson P, Casey A, Lawrence SJ, Kennedy NA, Kingstone K, Rogers P, Gillett PM, Wilson DC.

Am J Gastroenterol. 2012 Jun;107(6):941-9. doi: 10.1038/ajg.2012.33. Epub 2012 Feb 28.

PMID:
22370604
18.

Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.

Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, Gearry RB.

Inflamm Bowel Dis. 2015 Apr;21(4):824-31. doi: 10.1097/MIB.0000000000000341.

PMID:
25738372
19.

[Fecal calprotectin in the diagnosis of inflammatory bowel diseases].

Rodríguez-Moranta F, Lobatón T, Rodríguez-Alonso L, Guardiola J.

Gastroenterol Hepatol. 2013 Jun-Jul;36(6):400-6. doi: 10.1016/j.gastrohep.2012.10.008. Epub 2013 Feb 19. Spanish.

PMID:
23434080
20.

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.

Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.

Scand J Gastroenterol. 2016;51(2):196-202. doi: 10.3109/00365521.2015.1079924. Epub 2015 Sep 2.

PMID:
26329773

Supplemental Content

Support Center